Drugs / 177Lu-lilotomab satetraxetan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01796171 | Dec 2012 → Oct 2022 | follicular lymphoma | Nordic Nanovector | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-lilotomab satetraxetan | “single intravenous injection of the radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®)” PMID 41754790 ↗ Feb 2026 |
| Known as | Betalutin | “single intravenous injection of the radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®)” PMID 41754790 ↗ Feb 2026 |
| Modality | Other / unclassified | “radioimmunoconjugate 177Lu-lilotomab satetraxetan” PMID 41754790 ↗ Feb 2026 |
| Route | Intravenous | “single intravenous injection of the radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®)” PMID 41754790 ↗ Feb 2026 |